Snake venom toxins from Echis leucogaster

Snake venom toxins from Echis leucogaster, the White-bellied carpet viper, constitute a complex pharmacological cocktail primarily composed of enzymes and non-enzymatic proteins that disrupt hemostasis and cause tissue destruction (Latoxan, 2024; UniProt P0C7A8). The most clinically significant components are snake venom metalloproteinases (SVMPs), which induce systemic hemorrhage and activate prothrombin, leading to life-threatening consumption coagulopathy (PubMed, 2024; NIH, 2020). Other major toxin families include snake venom serine proteases (SVSPs), phospholipases A2 (PLA2s), and disintegrins such as leucogastrin-B, which collectively contribute to local edema, necrosis, and the inhibition of platelet aggregation (UniProt P0C7A8; NIH, 2024). Envenomation by this species is a medical emergency characterized by severe local damage and systemic bleeding, often requiring rapid administration of polyvalent antivenoms like SAIMR or FAV-Afrique (ResearchGate, 2026; Valenta et al., 2011). While antivenoms remain the standard of care, they face challenges such as limited cross-reactivity and the risk of anaphylaxis (NIH, 2020). Consequently, research is increasingly focused on small molecule inhibitors like varespladib and marimastat, which target the enzymatic cores of PLA2s and SVMPs, respectively, to provide broader and more stable therapeutic options (Casewell et al., 2020). Understanding the specific composition of Echis leucogaster venom is critical for developing effective treatments and managing the high morbidity associated with its bite in West African regions (PubMed, 2024).

Other names

White-bellied carpet viper venomRoman's saw-scaled viper venomEchis leucogaster venom proteins

Neutralization of toxic proteins by specific antibodies (antivenom); inhibition of enzymatic activity by small molecule inhibitors (e.g., zinc chelation for SVMPs, active site blocking for PLA2s).